Annual report pursuant to Section 13 and 15(d)

Intangible Assets and Impairment of Long-Lived Assets (Details)

v3.23.1
Intangible Assets and Impairment of Long-Lived Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Intangible Assets and Impairment of Long-Lived Assets (Details) [Line Items]          
Amortization expense $ 109,004 $ 116,297      
Traded stock (in Dollars per share)   $ 78      
Market value traded stock 3.39   $ 13.3 $ 16.96 $ 51.8
Fair market value 14,674,428   $ 18,872,850    
Loss on goodwill impairment 33,547,278        
Carrying amount 12,405,084        
Fair market value of assets 9,063,000        
Impaired assets $ 3,342,084        
IP R&D asset balance description This reduced the IP R&D asset balances of its CBR Pharma subsidiary and its 180 LP subsidiary to zero and $9,063,000, respectively, as of December 31, 2022; the total consolidated IP R&D asset balance is $9,063,000 after impairment.        
CBR Pharma [Member]          
Intangible Assets and Impairment of Long-Lived Assets (Details) [Line Items]          
Fair market value $ 1,462,084        
Carrying amount 1,462,084        
Fair market value of assets 0        
180 LP [Member]          
Intangible Assets and Impairment of Long-Lived Assets (Details) [Line Items]          
Fair market value 1,880,000        
Carrying amount 10,943,000        
Fair market value of assets $ 9,063,000